ライフサイエンスコーパス: bypass surgery

1 ry revascularization (800,000 PCI vs 350,000 bypass surgeries).

2 litus and patients following cardiopulmonary bypass surgery.

3 s coronary intervention, and coronary artery bypass surgery.

4 enefit of BIMA up to 10 years after coronary bypass surgery.

5 in CSCs isolated from 38 patients undergoing bypass surgery.

6 reflecting the vascular growth needed before bypass surgery.

7 apid antidiabetic effect of duodenal jejunal bypass surgery.

8 ing to the control of diabetes after gastric bypass surgery.

9 ous complications after laparoscopic gastric bypass surgery.

10 patients undergoing a priori coronary artery bypass surgery.

11 ic deterioration and decreased after gastric bypass surgery.

12 ed tunnel endoscopic harvesting for coronary bypass surgery.

13 ity or major morbidity after coronary artery bypass surgery.

14 ar all-cause mortality after coronary artery bypass surgery.

15 anagement intervention and Roux-en-Y gastric bypass surgery.

16 glucose and lipid homeostasis after duodenal bypass surgery.

17 aortic aneurysm repair, and lower extremity bypass surgery.

18 patients undergoing elective coronary artery bypass surgery.

19 onse of bariatric patients following gastric bypass surgery.

20 cebo for 2 to 6 weeks before coronary artery bypass surgery.

21 ternal mammary artery of patients undergoing bypass surgery.

22 more than 5 years following coronary artery bypass surgery.

23 usion in patients undergoing coronary artery bypass surgery.

24 idence of in-hospital mortality or emergency bypass surgery.

25 biopsy samples were obtained during coronary bypass surgery.

26 occur in patients undergoing cardiopulmonary bypass surgery.

27 ery with traditional on-pump coronary artery bypass surgery.

28 n great saphenous veins harvested at cardiac bypass surgery.

29 reatment of depression after coronary artery bypass surgery.

30 mal weight, morbidly obese, and post-gastric-bypass surgery.

31 of long-term survival after coronary artery bypass surgery.

32 to cardiac ischemia, such as during coronary bypass surgery.

33 d weight loss benefits observed post-gastric bypass surgery.

34 measures plus survival) for coronary artery bypass surgery.

35 e considered equivalent, if not superior, to bypass surgery.

36 e considered equivalent, if not superior, to bypass surgery.

37 s mellitus, hypertension, and prior coronary bypass surgery.

38 ed operative mortality after coronary artery bypass surgery.

39 linemic hypoglycemia after Roux-en-Y gastric bypass surgery.

40 72%) patients had a previous coronary artery bypass surgery.

41 ive coronary arteries, and often necessitate bypass surgery.

42 epeat percutaneous coronary intervention and bypass surgery.

43 recurrence to less than 5%, rivaling that of bypass surgery.

44 tive anatomy and complications after gastric bypass surgery.

45 mic inflammatory response to cardiopulmonary bypass surgery.

46 the molecular mechanisms underlying gastric bypass surgery.

47 it to combining ventricular restoration with bypass surgery.

48 e should not be a deterrent for recommending bypass surgery.

49 48 hours after the onset of cardiopulmonary bypass surgery.

50 ties, overcoming main challenges in arterial bypass surgery.

51 n resistance/diabetes after gastrointestinal bypass surgery.

52 be the greatest in those undergoing gastric bypass surgery.

53 +/- 6.3 kg/m(2); 46 +/- 11 y) during gastric-bypass surgery.

54 n resistance associated with cardiopulmonary bypass surgery.

55 ars) weight loss following Roux-en-Y gastric bypass surgery.

56 on of gut hormones following certain gastric bypass surgeries.

57 coronary intervention, 32%; coronary artery bypass surgery, 10%).

58 tained from 386 patients undergoing coronary bypass surgery (127 with type 2 diabetes).

59 7.1% vs 20.0%, P < .001) and coronary artery bypass surgery (2.7% vs 4.2%, P < .01).

60 y intervention (28%), urgent coronary artery bypass surgery (27.5%), maternal mortality (4%), and fet

61 d survived and not undergone coronary artery bypass surgery 30 days after discharge were followed up

62 ysm repair (51% vs 38%), and lower extremity bypass surgery (32% vs 3%).

63 Of 591 patients undergoing cardiopulmonary bypass surgery, 57 (9.6%) tested positive for anti-prota

64 coronary intervention, 38%; coronary artery bypass surgery, 7%).

65 (32.1% versus 23.8%; P<0.001), and coronary bypass surgery (9.2% versus 5.7%; P<0.001).

66 xcluding patients with prior coronary artery bypass surgery, 925 patients were included in the analys

67 Although gastric bypass surgery accounts for 80% of bariatric surgery in

68 tion (adjusted HR, 0.26; 95% CI, 0.13-0.54), bypass surgery (adjusted HR, 0.47; 95% CI, 0.30-0.73), o

69 in 53 patients who were undergoing coronary bypass surgery (age 60+/-11 years; 13% female).

70 ants 2.5 to 12 kg undergoing cardiopulmonary bypass surgery, aimed at (1) demonstrating the feasibili

71 rcutaneous coronary intervention and reduced bypass surgery along with improved clinical outcomes ove

72 rn after maternal bariatric gastrointestinal bypass surgery (AMS) are less obese and exhibit improved

73 erall, 6 of 168 patients had coronary artery bypass surgery and 33 of 168 had percutaneous coronary i

74 A cohort of 7925 patients undergoing gastric bypass surgery and 7925 group-matched, severely obese in

75 mong 9949 patients who had undergone gastric bypass surgery and 9628 severely obese persons who appli

76 etes mellitus-1 managed by Roux-en-Y gastric bypass surgery and a comparable group managed medically.

77 nd restenosis limit the long-term utility of bypass surgery and angioplasty due to pathological proli

78 domized revascularization candidates between bypass surgery and angioplasty.

79 the peri-infarct area has been performed at bypass surgery and by subendocardial injection in the ca

80 diabetes, the metabolic benefits of gastric bypass surgery and diet were similar and were apparently

81 er our understanding of SVG remodeling after bypass surgery and may guide future research to help pre

82 Both coronary artery bypass surgery and percutaneous intervention have been u

83 dysfunction underwent MCE 1 to 5 days before bypass surgery and repeat echocardiography at 3 to 4 mon

84 n usage within the 5 days preceding coronary bypass surgery and risk of adverse in-hospital postopera

85 farction, urgent or emergent coronary artery bypass surgery and stroke) and to construct a simple sco

86 Off-pump coronary bypass surgery and the newest generation of drug-eluting

87 wo other deaths occurred, one after coronary bypass surgery and the other from hepatic failure.

88 al infarction, and emergency coronary artery bypass surgery) and follow-up survival were compared bet

89 ans of percutaneous coronary intervention or bypass surgery) and to receive the best available medica

90 ous coronary angioplasty, or coronary artery bypass surgery) and total mortality (CHD, cardiovascular

91 aphenous vein graft occlusion after coronary bypass surgery), and particularly those with diabetes, u

92 atients, 13% had PCI, 2% had coronary artery bypass surgery, and 3% died during the readmission.

93 tal cohort of individuals undergoing gastric bypass surgery, and DMGV levels fell in parallel with im

94 llation, diabetes mellitus, previous cardiac bypass surgery, and higher implanter procedural volume w

95 vels of endogenous GLP-1 occur after gastric bypass surgery, and mechanistic studies indicate glucose

96 cannulated RAs as grafts in coronary artery bypass surgery, and there are no clear guidelines on the

97 We included eligible PCI, coronary artery bypass surgery, and valve surgery patients from 2010 to

98 litation referral after PCI, coronary artery bypass surgery, and valve surgery.

99 ntervention (angioplasty, or coronary artery bypass surgery), angina and/or unspecified ischaemic hea

100 ar disease, absence of prior coronary artery bypass surgery, angina, low body mass index (<21 kg/m(2)

101 n via percutaneous interventions or coronary bypass surgery are appropriate in specific cases or when

102 Patients undergoing isolated coronary artery bypass surgery at 2 hospitals were divided into derivati

103 2 whites undergoing isolated coronary artery bypass surgery at 663 Society of Thoracic Surgery Databa

104 ortality benefit in those undergoing gastric bypass surgery at ages younger than 35 years primarily d

105 SD BMI 54.7 +/- 12.6 kg/m(2)) during gastric bypass surgery at Barnes-Jewish Hospital.

106 The need for bypass surgery at one year was reduced among patients ra

107 dergoing first-time isolated coronary artery bypass surgery at our institution from January 2000 thro

108 or full service centers with coronary artery bypass surgery available.

109 ty, Minnesota, who underwent coronary artery bypass surgery between 1996 and 2007.

110 identified 6376 patients undergoing gastric bypass surgery between 2006 and 2008.

111 type 2 diabetes mellitus undergoing gastric bypass surgery between January 2000 and July 2004, 78 pa

112 cts were studied before and after intestinal bypass surgery (biliopancreatic diversion [BPD]).

113 or descending artery is standard in coronary bypass surgery, but controversy exists on the best secon

114 ith lower mortality rates in coronary artery bypass surgery, but how volume and quality of care relat

115 patients undergoing elective coronary artery bypass surgery (CABG) after cardiac catheterization.

116 Coronary bypass surgery (CABG) and angioplasty (PTCA) have been c

117 ondary preventive medications after coronary bypass surgery (CABG) and percutaneous coronary interven

118 The choice between coronary artery bypass surgery (CABG) and percutaneous coronary interven

119 Coronary artery bypass surgery (CABG) and percutaneous coronary interven

120 e completion angiogram after coronary artery bypass surgery (CABG) and simultaneous (1-stop) percutan

121 ations for optimal timing of coronary artery bypass surgery (CABG) in patients with non-ST-segment-el

122 erformed in conjunction with coronary artery bypass surgery (CABG) in the United States for asymptoma

123 d the incidence of AKI after coronary artery bypass surgery (CABG) or after percutaneous coronary int

124 determinant of early or late coronary artery bypass surgery (CABG) outcomes.

125 ous vein grafts to the aorta during coronary bypass surgery (CABG) without cross-clamping.

126 be stimulated at the time of coronary artery bypass surgery (CABG), and if dissection of this FP decr

127 xclusively in the setting of coronary artery bypass surgery (CABG), and no study has repeated delayed

128 ogistic regression modeling, coronary artery bypass surgery (CABG), either isolated or combined with

129 ality in patients undergoing coronary artery bypass surgery (CABG).

130 or late mortality following coronary artery bypass surgery (CABG).

131 vention (PCI) With Taxus and coronary artery bypass surgery (CABG)] score is a decision-making tool i

132 Mortality after coronary-artery bypass surgery (CABS) has fallen steadily over recent ye

133 Gastric bypass surgery can dramatically improve type 2 diabetes.

134 induced by cardiac arrest or cardiopulmonary bypass surgery, causes cell death in vulnerable hippocam

135 We conclude that in T2D, bypass surgery changes the postprandial response to a du

136 obese subjects undergoing Roux-en-Y gastric bypass surgery compared to lean controls undergoing elec

137 ter 10 years of follow-up, Roux-en-Y gastric bypass surgery, compared with nonsurgical medical manage

138 Cardiopulmonary bypass surgery (CPB) is associated with a high incidence

139 Patients who have undergone bypass surgery do not produce such plaque but instead fo

140 Prophylactic IVC filters for gastric bypass surgery do not reduce the risk of pulmonary embol

141 25; P<0.001), and history of coronary artery bypass surgery (DTR=2.81; P<0.001).

142 %) of 355 patients underwent aortic or iliac bypass surgery during the follow-up period.

143 bowel obstruction after laparoscopic gastric bypass surgery during the second and third trimesters.

144 ained ventricular tachycardia not related to bypass surgery, EF, age, left ventricular conduction abn

145 eeve gastrectomy (VSG) and Roux-en-Y gastric bypass surgeries for obesity.

146 s common following pediatric cardiopulmonary bypass surgery for congenital heart disease.

147 (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascular

148 (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascular

149 (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascular

150 Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascular

151 (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascular

152 (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascular

153 (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascular

154 (Evaluation of Xience Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascular

155 (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascular

156 risk factors for adverse outcomes after vein bypass surgery for limb salvage.

157 utaneous coronary intervention with coronary bypass surgery for multivessel coronary disease mandate

158 orld, and to date there is no alternative to bypass surgery for severe coronary atherosclerosis.

159 US Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries [S

160 US Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries [S

161 US Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries [S

162 US Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries) t

163 US Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries),

164 were performed in 72 patients after gastric bypass surgery for treatment of morbid obesity.

165 l management plus standard Roux-en-Y gastric bypass surgery (gastric bypass).

166 Gastric bypass surgery (GBP) promotes early improvements in gluc

167 epression and death by suicide after gastric bypass surgery (GBP).

168 ate that patients who have undergone gastric bypass surgery (GBS) have a higher risk of inpatient car

169 tudy was to test the hypothesis that gastric bypass surgery (GBS) would favorably impact cardiac remo

170 8 kg/m(2)) human subjects undergoing gastric bypass surgery (GBS).

171 ximately 18%) weight loss induced by gastric bypass (surgery group) or diet alone (diet group) in 22

172 s who sought and underwent Roux-en-Y gastric bypass (surgery group), 417 patients who sought but did

173 2.6%, 3.0%; P<0.001) and need for emergency bypass surgery (groups 4 to 1: 0.4%, 0.5%, 1.6%, 5%; P<0

174 Patients undergoing gastric bypass surgery had a significantly lower age-related inc

175 control group, the group undergoing gastric bypass surgery had a significantly reduced incidence of

176 The group undergoing gastric bypass surgery had greater percentage of excess weight l

177 at black patients undergoing coronary artery bypass surgery had worse outcomes than white patients, e

178 ity and gender to the outcomes of peripheral bypass surgery has been controversial.

179 k of atrial fibrillation (AF) after coronary bypass surgery has been related to redox state, inflamma

180 Bypass surgery has been shown to prolong life in patient

181 arch efforts, clinical practice for arterial bypass surgery has been stagnant, and engineered grafts

182 cutaneous coronary interventions or coronary bypass surgery have been shown to improve outcomes.

183 infarction hospitalization; coronary artery bypass surgery; heart valve repair/replacement; percutan

184 ed, resulting in angioplasty in 6 (9.8%) and bypass surgery in 1 (1.6%).

185 study sample (74.5%) underwent laparoscopic bypass surgery in 2005.

186 n prophylactic angioplasty in 18 (6.2%), and bypass surgery in 8 (2.8%) before listing.

187 gina, myocardial infarction, angioplasty, or bypass surgery in a relative <50 years of age.

188 secondary to ischemic cardiomyopathy (prior bypass surgery in all cases; left ventricular ejection f

189 and harms of laparoscopic Roux-en-Y gastric bypass surgery in patients defined by weight class (over

190 The efficacy of bypass surgery in patients with ischemic cardiomyopathy

191 feasible alternative to open coronary artery bypass surgery in selected patient populations.

192 ars undergoing isolated AVR (with or without bypass surgery) in 1045 US hospitals during 1999-2001 fr

193 l obstruction following laparoscopic gastric bypass surgery (incidence rates 46.5, 95% CI 38.0-56.9/1

194 matory status, and was restored upon gastric bypass surgery-induced weight loss in morbid obesity.

195 Although gastric bypass surgery induces rapid weight loss and ameliorates

196 30 children immediately postcardiopulmonary bypass surgery (infection-negative systemic inflammation

197 Vein graft failure following bypass surgery is a frequent and important clinical prob

198 Vein bypass surgery is an effective therapy for atherosclerot

199 within the 5 days preceding coronary artery bypass surgery is associated with a lower risk of postop

200 n graft failure within the first month after bypass surgery is largely because of thrombosis.

201 ion, and early revascularization with PCI or bypass surgery is now the preferred management strategy.

202 A decision for bypass surgery is often based on the durability of surgi

203 lihood of complications, and coronary artery bypass surgery is often required.

204 Gastric bypass surgery is protective against mortality even for

205 Gastric bypass surgery is the most effective treatment and is of

206 Recent and ongoing progress will make bypass surgery largely obsolete within the next several

207 We hypothesized that gastric bypass surgery leads to a lower incidence of heart failu

208 Gastric bypass surgery leads to marked improvements in glucose t

209 eral artery disease includes lower extremity bypass surgery (LEB) and peripheral endovascular interve

210 s who undergo laparoscopic Roux-en-Y gastric bypass surgery may be at increased risk for alcohol use

211 Coronary artery bypass surgery may be the preferred revascularization st

212 from gut reconstruction as seen with gastric bypass surgery most likely contributes to the superior e

213 tion (HCR) combines arterial coronary artery bypass surgery (most commonly minimally invasive) and pe

214 re defined as death, need for angioplasty or bypass surgery, myocardial infarction, and a >25% worsen

215 ceived either laparoscopic Roux-en-Y gastric bypass surgery (n = 100) or laparoscopic adjustable gast

216 trant (n = 3,806), diet (n = 458), and ileal bypass surgery (n = 838).

217 tained from obese individuals during gastric bypass surgeries [ n = 16; body mass index: 44.8 +/- 11.

218 Gastric bypass surgery not only induces remission of pharmacolog

219 pass, aortobifemoral bypass, coronary artery bypass surgery, oesophagectomy, colectomy, pancreatectom

220 ormed in 185 patients during coronary artery bypass surgery of whom 13 had a history of paroxysmal AF

221 ing evidence points to the effect of gastric-bypass surgery on body weight, including alteration of g

222 Our results show that duodenal bypass surgery on obese, insulin-resistant Zucker fa/fa

223 amine the effect of off-pump coronary artery bypass surgery on the risk of postoperative acute kidney

224 without procedure] to 55.3% [coronary artery bypass surgery only]).

225 s studies comparing off-pump coronary artery bypass surgery (OPCABG) to conventional techniques utili

226 f the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation,

227 knee arterial disease that limits the use of bypass surgery or balloon angioplasty.

228 arterial disease and is usually treated with bypass surgery or endovascular revascularization.

229 otential viable alternative to open coronary bypass surgery or multivessel stenting.

230 ar stenoses who are potential candidates for bypass surgery or neuroendovascular treatment, for the e

231 uited in patients undergoing coronary artery bypass surgery or percutaneous coronary interventions an

232 status, need for concomitant coronary artery bypass surgery, or baseline LVM.

233 all myocardial infarction, emergent coronary bypass surgery, or clinically indicated target lesion re

234 nts of myocardial infarction, same-admission bypass surgery, or death.

235 events (myocardial infarction, angioplasty, bypass surgery, or IHD death) among those screened and n

236 coronary intervention (PCI), coronary artery bypass surgery, or valve surgery be referred to cardiac

237 tients with cardiogenic shock, with previous bypass surgery, or who received fibrinolysis, 2947 patie

238 ation ("should be done") for a preference of bypass surgery over percutaneous coronary intervention.

239 ton, Massachusetts, and involved 770 gastric bypass surgery patients between January 1, 2007, and Dec

240 The 25 804 gastric bypass surgery patients had on average lost 18.8 kg more

241 re is increasing evidence that after gastric bypass surgery, patients and animal models show a decrea

242 n patients with a history of coronary artery bypass surgery (PCI-CABG) is limited and the long-term e

243 y and postoperative morbidity after coronary bypass surgery persist with Black patients and female pa

244 CAO and hemodynamic cerebral ischemia, EC-IC bypass surgery plus medical therapy compared with medica

245 or operative mortality after coronary artery bypass surgery, race does not appear to be a significant

246 Coronary artery bypass surgery rates increased significantly with increa

247 or treating depression after coronary artery bypass surgery, relative to usual care.

248 In patients with prior gastrointestinal bypass surgery, renal allografts are also at risk of oxa

249 who underwent laparoscopic Roux-en-Y gastric bypass surgery reported a significant increase in the fr

250 INTERPRETATION: Roux-en-Y gastric bypass surgery resulted in substantial and durable bodyw

251 Gastric bypass surgery resulted in the selective reduction of th

252 tes are comparable to historic single vessel bypass surgery revascularization rates.

253 tes mellitus shortly after Roux-en-Y gastric bypass surgery (RYGB) and before there is major weight l

254 Roux-en-Y gastric bypass surgery (RYGB) results in remission of insulin re

255 ment for morbid obesity is Roux-en-Y gastric bypass surgery (RYGB), which results in rapid remission

256 t T2D (n = 9) subjected to Roux-en-Y gastric bypass surgery (RYGB).

257 Roux-en-Y gastric bypass surgery (RYGBP), the most commonly performed proc

258 Patients undergoing gastric bypass surgery seen at a private surgical practice from

259 Lastly, duodenal bypass surgery selectively altered the tissue concentrat

260 at Abs to PRT/H occur commonly after cardiac bypass surgery, share a number of serologic features wit

261 samples from 35 of the sepsis and 28 of the bypass surgery subjects were available for screening wit

262 abetes remission following Roux-en-Y gastric bypass surgery, suggesting new therapeutic approaches ag

263 neurones were not reversed following gastric bypass surgery, suggesting that they may be due to diet,

264 Gastrointestinal bypass surgeries that result in rerouting and subsequent

265 ng-term complication to laparoscopic gastric bypass surgery that may be more common during pregnancy.

266 s frequently relapse after Roux-en-Y gastric bypass surgery, the authors sought to assess whether SRI

267 mong the 7925 patients who underwent gastric bypass surgery, the mean (SD) age at surgery was 39.5 (1

268 is commonly performed before coronary artery bypass surgery, there has yet to be a study examining th

269 l glycemia excursions increase after gastric bypass surgery; this effect is even greater among patien

270 ed to deliver effective guidance of coronary bypass surgery to a reduction of adverse cardiac outcome

271 rdial biopsies were obtained during coronary bypass surgery to assess glucose transporter (GLUT4) dis

272 atients with type 2 diabetes, adding gastric bypass surgery to lifestyle and medical management was a

273 Potential benefits of adding gastric bypass surgery to the best lifestyle and medical managem

274 alence of IPF in subjects undergoing gastric bypass surgery, to identify biochemical variables associ

275 e ICU after multiple complications following bypass surgery, under anticoagulation after a recent aor

276 abase (1986-2003) with prior coronary artery bypass surgery undergoing cardiac catheterization who ha

277 those undergoing and not undergoing gastric bypass surgery using HRs.

278 Gastric bypass surgery was associated with approximately one hal

279 ll associated with increased risk, and prior bypass surgery was associated with decreased risk.

280 Gastric bypass surgery was associated with improved long-term su

281 ntervention was performed in 59 percent, and bypass surgery was performed in 41 percent.

282 Coronary artery bypass surgery was performed in 44 cases because of comp

283 30 children immediately postcardiopulmonary bypass surgery was recruited.

284 , adjusted all-cause mortality after gastric bypass surgery was significantly lower for patients 35 t

285 Long-term total mortality after gastric bypass surgery was significantly reduced, particularly d

286 of systemic sterile stress, cardiopulmonary bypass surgery, we confirmed the initial induction of MR

287 For laparoscopic gastric bypass surgery, we used empirical Bayes techniques to cr

288 from 39 patients undergoing coronary artery bypass surgery were evaluated for the absence of collate

289 itant cardiac operations except for coronary bypass surgery were excluded.

290 ortality and morbidity after coronary artery bypass surgery were higher among black patients than amo

291 egments from 19 patients undergoing coronary bypass surgery were incubated with or without cytokines

292 tients without AF undergoing coronary artery bypass surgery were recruited.

293 to whites, blacks undergoing coronary artery bypass surgery were younger, yet had higher comorbiditie

294 se, followed by percutaneous intervention or bypass surgery where appropriate.

295 omes for patients undergoing primary gastric bypass surgery with those who had gastric bypass procedu

296 t studies comparing off-pump coronary artery bypass surgery with traditional on-pump coronary artery

297 ation (percutaneous coronary intervention or bypass surgery within 3 months) and non-early revascular

298 iatrogenic coronary dissection, or unplanned bypass surgery within 72 hours after diagnostic left hea

299 The effect of the use of coronary-artery bypass surgery without cardiopulmonary bypass and cardia

300 ended for all patients after coronary artery bypass surgery, yet little is known about the long-term